- Home
- ELLO vs ENGN Comparison
ELLO vs ENGN Comparison
Compare ELLO & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELLO
- ENGN
- Stock Information
- Founded
- ELLO 1987
- ENGN 1999
- Country
- ELLO Israel
- ENGN Canada
- Employees
- ELLO N/A
- ENGN N/A
- Industry
- ELLO Electric Utilities: Central
- ENGN
- Sector
- ELLO Utilities
- ENGN
- Exchange
- ELLO Nasdaq
- ENGN Nasdaq
- Market Cap
- ELLO 208.2M
- ENGN 191.1M
- IPO Year
- ELLO 1995
- ENGN N/A
- Fundamental
- Price
- ELLO $17.00
- ENGN $3.78
- Analyst Decision
- ELLO
- ENGN Buy
- Analyst Count
- ELLO 0
- ENGN 7
- Target Price
- ELLO N/A
- ENGN $23.29
- AVG Volume (30 Days)
- ELLO 11.7K
- ENGN 71.6K
- Earning Date
- ELLO 06-30-2025
- ENGN 09-09-2025
- Dividend Yield
- ELLO N/A
- ENGN N/A
- EPS Growth
- ELLO N/A
- ENGN N/A
- EPS
- ELLO 0.43
- ENGN N/A
- Revenue
- ELLO $44,405,534.00
- ENGN N/A
- Revenue This Year
- ELLO N/A
- ENGN N/A
- Revenue Next Year
- ELLO N/A
- ENGN N/A
- P/E Ratio
- ELLO $43.83
- ENGN N/A
- Revenue Growth
- ELLO N/A
- ENGN N/A
- 52 Week Low
- ELLO $11.30
- ENGN $2.65
- 52 Week High
- ELLO $20.81
- ENGN $11.00
- Technical
- Relative Strength Index (RSI)
- ELLO 55.71
- ENGN 54.41
- Support Level
- ELLO $15.40
- ENGN $3.25
- Resistance Level
- ELLO $17.50
- ENGN $3.98
- Average True Range (ATR)
- ELLO 0.59
- ENGN 0.24
- MACD
- ELLO -0.10
- ENGN 0.02
- Stochastic Oscillator
- ELLO 50.96
- ENGN 63.95
About ELLO Ellomay Capital Ltd (Israel)
Ellomay Capital Ltd is focused on the utility sector. It is an Israeli public company, which focuses its business in the energy and infrastructure sectors. The company's operating segment includes Photovoltaic power plants (PV Plants); Dorad Energy Ltd. (Dorad); Groen Gas Goor B.V. and a Pumped storage hydro power plant (Manara). It generates maximum revenue from the Dorad segment. Geographically, it derives a majority of its revenue from Spain.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.